1-6 of 6
Xavier Parot
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma

Open Access
Clinical Trials & Observations
Sarah A Holstein, Shebli Atrash, Hira Mian, Meletios Athanasios Dimopoulos, Fredrik Schjesvold, Rakesh Popat, Nishi Shah, Moshe E Gatt, Christian B. Gocke, Laurent Frenzel, Cyrille Touzeau, Meral Beksac, Salomon Manier, Hila Magen, Patrick Travis, Omar Nadeem, Kaveri Suryanarayan, Cheryl Li, Shuli Li, Allison Nelson, Dasha Cherepanov, Xavier Parot, Dan T Vogl
Journal: Blood
Blood blood.2024027873.
https://doi.org/10.1182/blood.2024027873
Published: 2025
Includes: Supplemental data
Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Open Access
Clinical Trials & Observations
Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don Benson, Maria Chaudry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman
Journal: Blood
Blood (2025) 145 (9): 944–955.
https://doi.org/10.1182/blood.2024026124
Published: 2025
Includes: Supplemental data
Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Shebli Atrash, Sarah A. Holstein, Hira Mian, Meletios A. Dimopoulos, Fredrik Schjesvold, Rakesh Popat, Nishi Shah, Moshe E Gatt, Christian B. Gocke, Laurent Frenzel, Cyrille Touzeau, Meral Beksac, Salomon Manier, Hila Magen, Patrick M. Travis, Omar Nadeem, Kaveri Suryanarayan, Shuli Li, Xavier Parot, Dan T. Vogl
Journal: Blood
Blood (2024) 144 (Supplement 1): 3355.
https://doi.org/10.1182/blood-2024-198119
Published: 2024
Journal Articles

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don M. Benson, Jr., Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman
Journal: Blood
Blood (2022) 140 (Supplement 1): 1357–1359.
https://doi.org/10.1182/blood-2022-162253
Published: 2022
Journal Articles

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Free
Dan T. Vogl, Jonathan L. Kaufman, Sarah A. Holstein, Shebli Atrash, Omar Nadeem, Murali Janakiram, Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Maria Chaudhry
Journal: Blood
Blood (2021) 138 (Supplement 1): 898.
https://doi.org/10.1182/blood-2021-148463
Published: 2021
Journal Articles

TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

Free
Dan T. Vogl, MD, Jonathan L. Kaufman, MD, Sara A. Holstein, MDPhD, Omar Nadeem, MD, Elizabeth O'Donnell, MD, Kaveri Suryanarayan, MD, Sabrina Collins, Xavier Parot, MD, Maria Chaudhry, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-141219
Published: 2020